Acute Leukemias in 2nd or subsequent CR
Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt's lymphoma: second or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
High risk hematologic malignancy\r\n* High risk acute lymphoblastic leukemia (ALL) in complete remission 1 (CR1); examples include, but not limited to: t(9;22), hypodiploid, minimal residual disease (MRD) > 1% at the end of induction, M2 or greater marrow at the end of induction, infants with mixed-lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk complete remission 2 (CR2); examples include, but not limited to t(9;22), bone marrow (BM) relapse < 36 months CR1, T-ALL, very early (< 6 months CR1) isolated central nervous system (CNS) relapse\r\n* ALL in complete remission 3 (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1 (diagnosis of AML includes myeloid sarcoma); examples include but not limited to: preceding myelodysplastic syndrome (MDS), 5q-, -5, -7, French-American-British Cooperative group (FAB) M6, FAB M7 not t(1;22), MRD > or = 5% on day 22 (AML08), MRD > 0.1% after two cycles of induction, M3 marrow after once cycle of induction, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* AML in relapse with < 25% blasts in BM\r\n* Therapy related AML, with prior malignancy in CR > 12 months\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myeloid leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* One of the following hematologic malignancies that are refractory (includes chemoresistant relapse or primary induction failure)\r\n** ALL\r\n** AML\r\n** CML (blast crisis)\r\n** Hodgkin or non-Hodgkin lymphoma
Acute leukemias in second (2nd) or subsequent remission
Biphenotypic/undifferentiated leukemias in first (1st) or subsequent complete remission (CR)
Burkitt's lymphoma: second or subsequent CR
Biphenotypic or undifferentiated leukemia in any CR or if in 1st relapse must have < 25% blasts in bone marrow (BM)
Biphenotypic or undifferentiated leukemia in any CR or if in first (1st) relapse must have < 25% blasts in BM
Burkitts lymphoma in CR2 or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
AML and ALL in 2nd or subsequent CR
Patients must have at least one of the following high-risk conditions listed below (criteria are consistent with existing criteria within Children's Oncology Group [COG] protocols):\r\n* Acute lymphocytic leukemia (ALL) in first complete remission (CR1) as defined by at least one of the following:\r\n** Hypodiploidy\r\n** Induction failure\r\n** Minimal residual disease (MRD) after consolidation\r\n* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:\r\n** High allelic ratio fms-related tyrosine kinase 3 (FLT3)/internal tandem duplications (ITD) positive (+)\r\n** Monosomy 7\r\n** Del (5q)\r\n** Standard risk cytogenetics with positive minimal residual disease at the end of Induction I chemotherapy (for patients being treated on or according to COG AAML1031 who have had MRD studies sent to Seattle or performed at their local institution where the flow assay is sensitive enough to detect >= 0.1% blasts)\r\n* Acute leukemias in 2nd or subsequent complete remission (CR) (CR >= 2)\r\n* Mixed phenotype/undifferentiated leukemias in 1st or subsequent CR\r\n* Secondary or therapy related leukemias in CR >= 1\r\n* Natural killer (NK) cell leukemia or NK cell lymphoblastic leukemia/lymphoma CR >= 1\r\n* Myelodysplastic syndrome (MDS)\r\n* Juvenile myelomonocytic leukemia (JMML) (patients are eligible if they are not eligible for COG1221)\r\n* Prior transplant eligible if =< 18 years old (yo), >= 1 year has elapsed since BMT, and patient is off immunosuppression for >= 3 months with no GVHD; patients who have had a prior chemotherapy based preparative regimen are allowed to receive a TBI based prep, regardless of their disease\r\n* No known active central nervous system (CNS) involvement or extramedullary involvement by malignancy; such disease treated into remission is permitted\r\n* Remission is defined as morphology with < 5% blasts with no morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow with > 20% cellularity
Relapse after achieving a CR following the first or subsequent relapse (i.e., ? 2 relapses) OR
Acute Myelogenous Leukemia (AML) in high risk 1st or subsequent CR
Biphenotypic or undifferentiated leukemia in 1st or subsequent CR
High-risk hematologic malignancy\r\n* Very high risk acute lymphocytic leukemia (ALL) in first complete remission (CR1); examples include, but not limited to hypodiploid M2 or greater marrow at the end of induction, infants with mixed lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk second complete remission (CR2); examples include but not limited to bone marrow (BM) relapse < 36 months (mo); CR1, T-ALL, very early (< 6 mo CR1) isolated central nervous system (CNS) relapse\r\n* ALL in third complete remission (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1; examples include but not limited to preceding myelodysplastic syndromes (MDS), 5q-, -5, -7, French American British (FAB) M6, FAB M7 not t(1;22), minimal residual disease (MRD) >= 5% on day 22 (AML08), M3 marrow after induction 1, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* Therapy related AML, with prior malignancy in CR > 12 mo\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myelogenous leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Refractory hematologic malignancies (ALL, AML, CML in blast crisis, Hodgkin or non-Hodgkin lymphoma) due to chemoresistant relapse or primary induction failure\r\n* All patients with evidence of CNS leukemia must be treated and be in CNS CR to be eligible for study
Acute leukemias in 2nd or subsequent CR
Biphenotypic/undifferentiated in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
Acute leukemia in complete remission (CR)1 or second/subsequent CR
Non-Hodgkin lymphoma in high risk CR1 or subsequent CR (by clinical, cytogenetic or molecular criteria), primary induction failure (PIF) or relapsed with chemosensitive disease; SD may be included if no mass > 3 cm
Acute lymphoblastic leukemia (ALL) with any of the following:\r\n* In CR1 or subsequent complete remission (CR2, CR3, etc.)\r\n* Primary refractory or relapsed ALL with no more than one of the following adverse features according to modified CIBMTR criteria\r\n** Second or subsequent relapse\r\n** Bone marrow blasts > 25% at time of enrollment\r\n** Age > 40 years
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt’s lymphoma in second complete remission (CR2) or subsequent CR